Abdominal obesity In a 12-month clinical trial published in 2010, which involved 404 HIV-infected patients with excess abdominal fat, the group that received 2mg of tesamorelin per day saw an 18% decrease in visceral fat compared to placebo.9 There are two things to note in order to appreciate the full scope of these findings: Visceral fat (i.e., fat accumulation around the abdominal organs) is famously stubborn and cant be burned selectively through exercise
Gastrointestinal lining & gut integrity Derived from a protective sequence found in gastric juice, BPC-157 is studied for its supportive relationship with the gastrointestinal tract
PubMed, Joshi, Deepmala, et al
refers to DNA methylation in the promoter region of GSTP1 gene responsible for epigenetic silencing of this isoenzyme
Conclusion Stacking Tesamorelin, Ipamorelin, and CJC-1295 can unlock some of the most advanced benefits peptide therapy has to offer